Uploaded May 2021 | Updated September 2026, 2 weeks ago
For translational and clinical research in hemato-oncology, the ability to identify and measure rare nucleic acid (NA) sequences is essential. Droplet digital PCR (ddPCR) enables absolute quantification of amplified DNA and RNA for detection and monitoring of cancer to give users the most reliable answers for their hemato-oncology questions, without the need for a standard curve. In this video testimonial, learn how Simona Soverini, PhD, assistant professor of Hematology at the University of Bologna, confirms that "Droplet digital PCR will become the method of choice for BCR-ABL1 TKD mutation testing: leading to sensitive and accurate screening for clinically actionable mutations using a more cost effective, fast and widely available technology. This is crucial for better management of tyrosine kinase inhibitor-resistant CML and Ph+ ALL patients across laboratories worldwide."
Learn more at bio-rad.com/hemonc
Subscribe to the Bio-Rad channel: youtube.com/user/BioRadLifeScience?sub_confirmation=1
We Are Bio-Rad.
Our mission: To provide useful, high-quality products and services that advance scientific discovery and improve healthcare. At Bio-Rad, we are united behind this effort. These two objectives are the driving force behind every decision we make, from developing innovative ideas to building global solutions that help solve our customers' greatest challenges.
Connect with Bio-Rad Online:
Website: bio-rad.com
LinkedIn: linkedin.com/company/1613226
Facebook: facebook.com/biorad
Twitter: twitter.com/BioRadLifeSci
Instagram: @BioRadLabs
Snapchat: @BioRadLabs
©2021 Bio-Rad is a trademark of Bio-Rad Laboratories, Inc. in certain jurisdictions. All trademarks used herein are the property of their respective owner.
Music used by permission granted by royalty-free license from Pond5.com
For translational and clinical research in hemato-oncology, the ability to identify and measure rare nucleic acid (NA) sequences is essential. Droplet digital PCR (ddPCR) enables absolute quantification of amplified DNA and RNA for detection and monitoring of cancer to give users the most reliable answers for their hemato-oncology questions, without the need for a standard curve. In this video testimonial, learn how Simona Soverini, PhD, assistant professor of Hematology at the University of Bologna, confirms that "Droplet digital PCR will become the method of choice for BCR-ABL1 TKD mutation testing: leading to sensitive and accurate screening for clinically actionable mutations using a more cost effective, fast and widely available technology. This is crucial for better management of tyrosine kinase inhibitor-resistant CML and Ph+ ALL patients across laboratories worldwide."
Learn more at bio-rad.com/hemonc
Subscribe to the Bio-Rad channel: youtube.com/user/BioRadLifeScience?sub_confirmation=1
We Are Bio-Rad.
Our mission: To provide useful, high-quality products and services that advance scientific discovery and improve healthcare. At Bio-Rad, we are united behind this effort. These two objectives are the driving force behind every decision we make, from developing innovative ideas to building global solutions that help solve our customers' greatest challenges.
Connect with Bio-Rad Online:
Website: bio-rad.com
LinkedIn: linkedin.com/company/1613226
Facebook: facebook.com/biorad
Twitter: twitter.com/BioRadLifeSci
Instagram: @BioRadLabs
Snapchat: @BioRadLabs
©2021 Bio-Rad is a trademark of Bio-Rad Laboratories, Inc. in certain jurisdictions. All trademarks used herein are the property of their respective owner.
Music used by permission granted by royalty-free license from Pond5.com
